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Introduction {#sec1}
============

Functional vascular networks form as a result of a well-coordinated series of angiogenic events regulating endothelial cell (EC) proliferation, differentiation, polarization, and gene programming to produce stable tubular structures with specific barrier properties ([@bib17], [@bib77]). In the retina, angiogenesis occurs during postnatal stages when ECs from the brain invade the optic nerve, emerge from it, and spread over and within the retinal neuroepithelium ([@bib23]). This angiogenic process is coordinated with the simultaneous formation of a blood-retinal barrier wherein the paracellular permeability between adjacent ECs and transcellular transport across ECs are tightly regulated by junctional protein complexes and transporter proteins, respectively ([@bib69]). Cells within the cohesive vascular wall have cadherin-based adhesions at cell-cell junctions and integrin-based focal adhesions to cell-extracellular matrix (ECM) contacts. ECM proteins, in particular, form a network of fibrillary and fibrous proteins and glycans that are critical for all aspects of vascular growth and regeneration ([@bib8]). ECM proteins provide both anchorage points to the cells and chemical cues for directional migration, morphogenesis, and stability. In addition, EC-ECM interactions contribute to the acquisition of EC barrier properties appropriate for the nervous system ([@bib59], [@bib60]). However, the diversity of both the matrisome components (which constitute \>1% of the proteome) and the mechanisms controlling the synthesis, composition, and remodeling of ECM proteins is suggestive of an intricate level of complexity for the control of angiogenesis and barriergenesis ([@bib10]).

Connective tissue growth factor (CTGF) is a candidate ECM protein whose precise function in the vascular matrix is largely unknown. *CTGF* was originally isolated by differential screening of cDNA libraries prepared from HUVECs and NIH 3T3 fibroblasts ([@bib58]). The protein was named CTGF because of its mitogenic activity vis-à-vis fibroblasts and cultured ECs. CTGF is also referred to as cellular communication network 2 (CCN2) by virtue of its multimodular and structural analogy to the CCN family of proteins ([@bib37], [@bib54]). The primary *CTGF* translational product is a ∼40-kDa protein that contains 38 conserved cysteine residues dispersed throughout four distinct structural modules. CTGF elicits its biological activities through binding to various cell surface receptors including integrin receptors, cell surface heparan sulfate proteoglycans (HSPGs), low-density lipoprotein receptor-related proteins (LRPs), and TrkA in a cell type- and context-dependent manner ([@bib24], [@bib38]). It was suggested that such interactions enable CTGF to regulate a variety of cellular functions including cell adhesion, proliferation, migration, differentiation, survival, and ECM synthesis. In addition, *in vitro* assays showed that the CTGF N-terminal and C-terminal moieties interact with glycoproteins, proteoglycans, growth factors, and proteases, although the *in vivo* significance of such interactions is not well understood ([@bib18], [@bib28], [@bib30], [@bib55]). Global *CTGF* deficiency in mice demonstrated the importance of CTGF in cardiovascular and skeletal development, as *CTGF*-null mice exhibited defects in basic lung development and failed thoracic expansion, leading to perinatal lethality ([@bib31]). Although no overt vascular alterations were observed in *CTGF*-deficient mice during the initial formation of the primitive blood vessels, deficiencies in the endocrine cell lineage and reduced growth plate angiogenesis were noted. In adults, CTGF plays an important role in wound repair and CTGF protein levels correlate with many vascular and inflammatory diseases such as arthritis, diabetic nephropathy, and retinopathy ([@bib15], [@bib41], [@bib49], [@bib57], [@bib65]). In a rat model of glomerulonephritis, *CTGF* levels were elevated in areas of crescentic extracapillary proliferation, periglomerular fibrosis, and interstitial foci ([@bib26], [@bib68]). Although these *in vivo* studies suggested a potentially important role of CTGF in physiological and pathological angiogenesis, the specific mechanisms whereby CTGF regulates blood vessel development and function remain to be investigated.

Here we provide the first evidence that CTGF directly regulates retinal tissue vascularization and blood barrier integrity. We show that the loss of *CTGF* function impairs a genetic angiogenic program involved in vessel sprout morphogenesis and branching and barrier integrity. We further provide data about exemplar CTGF target genes such as yes-associated protein (YAP), which when re-expressed in the vasculature, rescues, at least in part, transcriptional programs associated with *CTGF* deficiency. Our results shed light on the genetic landscape responsible for CTGF-dependent regulation of proper vessel formation and function.

Results {#sec2}
=======

Expression and Cellular Localization of CTGF in the Postnatal and Adult Retinal Vasculature {#sec2.1}
-------------------------------------------------------------------------------------------

The retina is a complex neurovascular tissue organized into three cellular and two synaptic layers supported by a tripartite intraretinal vascular network. In mice, the retina is supported by three interconnected vascular layers that develop postnatally, making this model particularly useful for assessing the roles of genes potentially relevant to human vascular development and function ([@bib43]). To determine the expression pattern and cellular sources of CTGF during retinal vessel development, we used a CTGF:GFP bacterial artificial chromosome transgenic mouse line in which the green fluorescent protein (GFP) reporter gene was placed downstream of a large *CTGF* promoter segment (\>100 kb). Both endogenous *CTGF* and *GFP* transcript levels increased progressively as the superficial and deeper capillary plexuses invested the retina ([Figure 1](#fig1){ref-type="fig"}A). The dynamic *CTGF*:*GFP* expression pattern, which recapitulates endogenous *CTGF* transcript levels, suggests that the *CTGF* promoter-*GFP* reporter transgene contains the relevant *cis*-regulatory elements that regulate the *CTGF* gene *in vivo*. Similarly, CTGF protein levels progressively increased during retinal vessel development and plateaued during adult life ([Figures 1](#fig1){ref-type="fig"}B and 1C), indicating a constitutive expression of *CTGF* in the retinal tissue. We further examined the cellular sources of the CTGF:GFP signal in retinal flat mounts at P2, P6, and P28. As shown in [Figure 1](#fig1){ref-type="fig"}D, the reporter expression was found mainly in the expanding endothelial network stained with isolectin B4 (IB4) at P2 and P6 and persisted throughout the postnatal and adult periods. Further detailed analysis revealed a robust expression of *CTGF* in the ECs of the sprouting primary capillary plexus ([Figure 1](#fig1){ref-type="fig"}E). Endothelial tip cells with their filopodial extensions exhibited little or no CTGF:GFP signal ([Figure 1](#fig1){ref-type="fig"}F), whereas the trailing stalk ECs showed a strong CTGF:GFP signal indicating that CTGF potentially regulates stalk cell function including proliferation, lumenization, and stabilization. In addition, as the vascular tree developed, the CTGF:GFP signal spread into neuron-glial 2 (NG2)-positive mural cells (i.e., pericytes) of small and large vessels. In the retina, despite their small caliber, differences in vessel diameter distinguish arteries/arterioles and veins/venules. NG2-positive mural cells of the retinal arteries and capillaries ([Figure S1](#mmc1){ref-type="supplementary-material"}A) expressed the CTGF:GFP signal ([Figure 1](#fig1){ref-type="fig"}G). The larger veins similarly expressed the CTGF:GFP signal in their mural NG2-negative desmin-positive cells, but little to no *CTGF* expression appeared in venous ECs ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Moreover, detailed analysis of tissue cross sections revealed the CTGF:GFP signal in glutamine synthase (GS)^+^ Müller cells and Iba-1^+^ microglia, particularly those of the inner layer ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1D). Expression of *CTGF* was not associated with astrocytes (data not shown), even though these cells are a major source of vascular endothelial growth factor (VEGF), a bona fide regulator of *CTGF* expression in cultured cells ([@bib3], [@bib47], [@bib64]). The brain vasculature, which is similar in its complexity and properties to the retinal vasculature, exhibited a strong expression of the CTGF:GFP marker as well ([Figure S1](#mmc1){ref-type="supplementary-material"}E). Thus, CTGF exhibits heterogeneous and spatiotemporal expression patterns during vessel morphogenesis and a sustained expression in the adult vasculature of the central nervous system.Figure 1Expression and Cellular Localization of CTGF in the Postnatal and Adult Retinal Vasculature(A) Analysis of *CTGF* and *GFP* transcript levels in the *CTGF*:*GFP* reporter transgenic mouse strain during postnatal development of the retinal vasculature by real-time PCR. *CTGF* and *GFP* mRNA levels were normalized to those of *GAPDH*. Data are means ± standard error (SE) (n = 4).(B and C) (B) Analysis of CTGF protein levels in WT mouse retinas by western blotting. (C) CTGF protein bands were quantified by densitometric scanning. Error bars are SE of the means (n = 4).(D) Unstained (upper panels) and IB4-stained (red) flat-mounted retinas of P2, P6, and P28 *CTGF-GFP* reporter mice. Merged images in the lower panels show IB4 colocalization with the CTGF:GFP signal.(E and F) High-magnification images of retinal flat mounts of *CTGF*:*GFP* reporter mice stained with (E) IB4 and (F) Col4A1 antibody, respectively. Arrows and arrowheads indicate CTGF-GFP reporter signals in endothelial stalk cells and lack thereof in tip cells, respectively.(G) NG2 marker expression in mouse retinal flat mounts. Note the colocalization of the CTGF:GFP signal with the NG2 marker in small arteries and capillaries.See also [Figure S1.](#mmc1){ref-type="supplementary-material"}

Loss of *CTGF* Function Altered Normal Vessel Growth and Morphogenesis {#sec2.2}
----------------------------------------------------------------------

As a secreted protein, CTGF exerts autocrine and paracrine actions because it localizes not only within the interstitial ECM but also pericellularly, due to its heparin-binding activity ([@bib35]). To gain new insights into the function of vascular cell-derived CTGF, we examined the retinal vascular changes associated with global, EC-, or pericyte-specific loss of *CTGF* function. We used a *CTGF* mutant strain in which *loxP* sites had been engineered to flank exons 1 and 2 ([@bib45]) ([Figure S2](#mmc1){ref-type="supplementary-material"}A). These *CTGF*^flox/flox^ mice were crossed with transgenic Cre mice bearing an inducible Cre recombinase under the control of the ubiquitin C (*UBC*), *Cdh5*, or *Cspg*4 promoter to produce mouse mutants with global, EC-, and pericyte-specific deletion of *CTGF* (hereafter referred to as *UBC*Δ*CTGF*, *Cdh5*Δ*CTGF,* and *Cspg*Δ*CTGF*), respectively ([Figure S2](#mmc1){ref-type="supplementary-material"}B). The expression of *CTGF* was analyzed by qPCR to confirm its knockdown after three consecutive 4-hydroxytamoxifen (4HT) injections at P1, P2, and P3. *UBC*-, *Cdh5*-, and *Cspg*4-CreER^T2^ recombination with floxed alleles effectively reduced *CTGF* mRNA levels by \>85%, 55%, and 50% compared with wild-type (WT) (i.e., *CTGF*^flox/flox^) mice, respectively ([Figure S2](#mmc1){ref-type="supplementary-material"}C). CTGF protein levels were consistent with those of *CTGF* mRNA in WT and mutant mice ([Figure S2](#mmc1){ref-type="supplementary-material"}D). The EC- and pericyte-specific knockdown was not fully penetrant due to the expression of *CTGF* by cells other than ECs and pericytes, respectively. The retinal vascular phenotypes were examined at P7 when the vasculature was not only still growing but also had acquired tissue- and barrier-specific properties to support organ function. Retinas from 4HT- or corn oil-injected littermate *UBC*-CreER^T2^, *Cdh5*(*PAC)-CreER*^*T2*^, and *Cspg4-CreER*^*T2*^ exhibited a vascular phenotype identical to *CTGF*^flox/flox^ mouse retinas and were used as controls in all experiments. As shown in [Figures 2](#fig2){ref-type="fig"}A--2D, global loss of *CTGF* function resulted in a significant reduction of microvessel density, vascular branching, and vascular area. Arteriovenous differentiation and vascular expansion to the retinal edge were not affected, whereas the vascular network was partially shaped into rudimentary arterioles, venules, and capillaries. BrdU^+^ cell count at the angiogenic front showed a 45% reduction of cell proliferation ([Figure 2](#fig2){ref-type="fig"}E). Pericyte coverage (normalized to vascular area) was unaffected in *UBC*Δ*CTGF* mutant mouse vessels suggesting that *CTGF* loss had no apparent effect on mural cell recruitment to the vasculature ([Figure 2](#fig2){ref-type="fig"}F). Similar to global *CTGF* deficiency, EC-specific *CTGF* deletion induced a significant decrease in vascular area, branching points, and cell proliferation, and simultaneous increase of vascular lacunarity, although these alterations were slightly milder than those of the *UBC*Δ*CTGF* mutants ([Figures 2](#fig2){ref-type="fig"}G--2K). Conversely, the retinal vasculature in mice with pericyte-specific deletion of *CTGF* (i.e., *Cspg*Δ*CTGF*) closely resembled that in the WT control with respect to vascular morphology, architecture, and density ([Figures 2](#fig2){ref-type="fig"}L--2O), indicating that pericyte-derived *CTGF* had no major effect on retinal vascular development. Thus, *CTGF* deficiency in the endothelium recapitulates, at least in part, the global loss-of-function phenotype.Figure 2Loss of CTGF Function Altered Normal Vessel Growth and Morphogenesis(A) IB4-stained whole retinal flat mounts of WT (a) and *UBCΔCTGF* (b) mice. Quantitative analyses of vascular parameters were performed with AngioTool software (c and d). The vasculature outline, skeleton, and branching points were denoted in white, red, and green, respectively.(B--D) Graphical representations of the changes in (B) vascular area, (C) junction density, and (D) lacunarity between WT and *UBCΔCTGF* mouse retinas. ∗p \< 0.001 versus *CTGF*^*+/+*^ (n = 5).(E) Number of BrdU^+^ proliferating ECs per retinal area unit. ∗∗p \< 0.05 versus *CTGF*^*+/+*^ (n = 5).(F) Representative immunofluorescence images of dual IB4 (red) and NG2 (green) staining of whole-mount retinas of *CTGF*^*+/+*^ and *UBCΔCTGF* mice.(G) IB4-stained whole retinal mounts of WT (a) and *Cdh5ΔCTGF* (b) mice and associated AngioTool-analyzed images (c and d), respectively.(H--K) Graphical representations of the changes in (H) vascular surface, (I) junction density, and (J) lacunarity between WT and *Cdh5ΔCTGF* mouse retinas. BrdU^+^ cell count in the WT and mutant mouse retinas is shown in (K). ∗p \< 0.05 versus *CTGF*^*+/+*^ (n = 5).(L--O) Effects of pericyte-specific deletion of *CTGF* on the retinal vascular phenotype. Vascular parameters and proliferating cell counts were determined as described in (B--E).See also [Figure S2.](#mmc1){ref-type="supplementary-material"}

Loss of Blood Barrier Function following Global and EC-Specific Deletion of *CTGF* {#sec2.3}
----------------------------------------------------------------------------------

During vessel development, ECs tightly coordinate angiogenesis with vascular barrier formation. The latter involves the expression and engagement of tight junction (TJ) and adherens junction (AJ) proteins as well as expression of transporter proteins that limit paracellular and transcellular permeability between and across ECs ([@bib19]). To assess the effects of CTGF on barrier function, we examined the tissue localization of retro-orbitally-injected fluorescein isothiocyanate (FITC)-albumin, which does not traverse the vascular barrier under physiological conditions. In WT mice, the injected tracer was confined to the intravascular space of the retina ([Figure 3](#fig3){ref-type="fig"}A \[a and b\]). However, both *UBC*Δ*CTGF* and *Cdh5*Δ*CTGF* mutant mice exhibited extensive vascular leakage, indicated by a diffuse hyperfluorescent background and patchy hyperfluorescence in the extravascular space ([Figure 3](#fig3){ref-type="fig"}A \[c--f\]). Conversely, pericyte-specific deletion of *CTGF* did not result in overt signs of FITC-albumin extravasation, which, in most cases, was similar to that of WT mouse retinas ([Figure 3](#fig3){ref-type="fig"}A \[g and h\]). Leakage of Evans Blue (EB), which rapidly binds to plasma albumin, was 4- to 9-fold higher in retinas of *UBC*Δ*CTGF* and *Cdh5*Δ*CTGF* mutant mice, respectively, than that of WT controls ([Figure 3](#fig3){ref-type="fig"}B). There was no significant difference between WT and *Cspg*Δ*CTGF* mice with respect to EB leakage, which is consistent with the FITC-albumin results. Likewise, FITC-albumin extravasation was observed in the brain vasculature of the mutant mice indicating a defective blood-brain barrier as well ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Retro-orbital injection of Alexa Fluor 555-conjugated cadaverine, a small molecule (950 Da) reaching the size limit for passive paracellular transport through endothelial TJs, resulted in a remarkable infiltration of this tracer in the retinal and brain parenchyma of *CTGF*-deficient mice ([Figures S3](#mmc1){ref-type="supplementary-material"}B and S3C). Thus, loss of *CTGF* function caused paracellular barrier disruption in the retina and brain. Furthermore, we determined whether the expression of *CTGF* is required for barrier maintenance by analyzing retinal vascular barrier permeability in adult (P36) mice following 4HT injection a week prior. As shown in [Figure 3](#fig3){ref-type="fig"}C, *Cdh5*Δ*CTGF* retinas showed numerous bright extravascular spots due to FITC-albumin leakage from the retinal vasculature. In contrast, age-matched littermates showed no tracer leakage in the retinal parenchyma. Vascular leakage index was 41% higher in *CTGF* mutant compared with age-matched WT retinas ([Figure 3](#fig3){ref-type="fig"}D), indicating the importance of CTGF signals in blood-retinal barrier maintenance as well.Figure 3Loss of the Blood Barrier Function Following Global and EC-Specific Deletion of *CTGF*(A) Retinal flat mounts from *CTGF*^+/+^ (a and b), *UBC*Δ*CTGF* (c and d), *Cdh5*Δ*CTGF* (e and f), and *Cspg*Δ*CTGF* (g and h) mice following retro-orbital injection of FITC-albumin. Note that the tracer remained confined to the vascular lumen in *CTGF*^+/+^ and *Cspg*Δ*CTGF* mouse retinas. Note the hyperfluorescence of FITC-albumin in the retinal parenchyma as a result of FITC-albumin extravasation/leakage in *UBC*Δ*CTGF* and *Cdh5*Δ*CTGF* mouse retinas.(B) Vascular permeability index was normalized to total vascular area. ∗∗ p\<0.05 *versus CTGF^+/+^*.(C) FITC-albumin-injected retinal flat mounts from *CTGF*^+/+^ and *Cdh5*Δ*CTGF* adult (P36) mice that have received three consecutive injections of 4HT a week prior.(D) Vascular permeability index measured as described in (B). Values are means ± SE (n = 3). Values in *Cdh5*Δ*CTGF* mice were set to 100% to facilitate comparisons among animals. ∗,p\<0.05 *versus* *CTGF^+/+^*.See also [Figure S3.](#mmc1){ref-type="supplementary-material"}

Molecular Signature of *CTGF* during Retinal Vascular Development {#sec2.4}
-----------------------------------------------------------------

The formation of an organized retinal vasculature depends on signaling among different vascular and non-vascular cellular components of the retina including ECs, mural cells, neurons, glia, and immune cells. As an ECM protein, CTGF signals may affect the interactions among all these cellular components. To determine the global genetic bases of CTGF-dependent regulation of vascular growth and barrier function, we examined the transcriptomic differences between *CTGF*^+/+^ and *UBC*Δ*CTGF* mutant mouse retinas through RNA sequencing (RNA-seq)-based gene profiling. Following three consecutive 4HT injections from P1 onward, retinas from three different litters of *CTGF*^flox/flox^ and *CTGF*^flox/flox^-*UBC*-CreER^T2^ intercrosses were harvested at P7 and processed for total RNA extraction and gene profiling. Unsupervised hierarchical clustering and principal-component analysis demonstrated clear segregation and reproducibility of the obtained gene expression profiles for WT and *UBC*Δ*CTGF* mutants (Pearson\'s correlation coefficient ρ = 0.94) ([Figures S3](#mmc1){ref-type="supplementary-material"}A--S3C). The candidate CTGF-regulated genes encode proteins with a wide range of biological activities, likely reflecting the large diversity of cell types and circuits in the retina ([Figure S4](#mmc1){ref-type="supplementary-material"}D). Genes that encode proteins for the biosynthesis of RNA, macromolecules, nucleobase-containing compounds, neurogenesis, and RNA polymerase transcription were highly differentially expressed between WT and mutant retinas.

To expand our RNA-seq data analysis beyond the initial cutoff parameters, which often are subjective, arbitrary, and biologically unjustified, we used gene set enrichment analysis (GSEA) to map all detected unfiltered genes to defined gene sets (e.g., pathways), irrespective of their individual change in expression ([@bib62]). We identified 209 significantly changed genes (133 downregulated and 76 upregulated genes) in *UBC*Δ*CTGF* compared with *CTGF*^+/+^ retinas (absolute log~2~ fold change \>0.5, p \< 0.05) ([Figure 4](#fig4){ref-type="fig"}A). When the normalized transcriptomic data were compared to 1,454 Gene Ontology gene sets in the GSEA Molecular Signatures Database (i.e., MSigDB) ([@bib44]), 20 gene sets were significantly enriched in the *CTGF*^+/+^ or *UBC*Δ*CTGF* group. Of these, 13 were closely related to neuronal progenitor differentiation linked to cone rod homeobox (CRX) pathway, cell cycle regulation (i.e., cyclins, p53, SRC, Kras), cell survival (i.e., Akt), and inflammation pathways (i.e., IL-15, NF-κB) ([Figure 4](#fig4){ref-type="fig"}B). Gene sets of the platelet-derived growth factor and mTOR pathways were similarly downregulated in *UBC*Δ*CTGF*. Other core-enriched differentially expressed genes were involved in the regulation of tip cell differentiation, angiogenesis, ECM, and ECM metabolic pathways ([Figures 4](#fig4){ref-type="fig"}C--4E). In addition, *CTGF* deficiency resulted in downregulation of angiopoietin 1, ROBO1, integrin β1, Slit-1, Ephrin B2, Ephrin Receptor B4, and Dll-1, and upregulation of integrin β1-binding protein 1 and thrombospondin 1. Downregulated ECM protein genes included laminin 4, elastin, secreted protein acidic and cysteine rich (SPARC), fibrillin-2, glypican 5, collagen 4A1, and tenascin-C, whereas vitronectin, Col17A1, Col16A1, and Col5A3 genes were upregulated upon *CTGF* deletion. Genes encoding growth factors such as insulin-like growth factor-I (IGF-I), pleiotrophin, opticin, LTBP-1, transforming growth factor (TGF)-β1, TGF-β2, and fibroblast growth factor (FGF)-10 were downregulated in *UBC*Δ*CTGF* mutant mice. These results are suggestive of an important role of CTGF in regulating angiogenesis-related processes such as cell growth, adhesion, migration and guidance, as well as cell-ECM interactions. Importantly, the expression of several transcriptional regulator genes (e.g., YAP, TEA domain \[TEAD\], NFAT5, and SRF) was downregulated upon loss of *CTGF* function. Transcription factors are endpoints of a network of signaling pathways enabling the cells to process signals they receive simultaneously from many different receptors. The multitude of transcription factors affected by *CTGF* deletion suggests that CTGF signals impact global mechanisms of gene regulation.Figure 4Molecular Signature of CTGF During Retinal Vascular Development(A) GSEA-generated heatmaps of defined gene sets enriched at the top of a gene list ordered on the basis of expression differences between *CTGF*^+/+^ and *UBC*Δ*CTGF* mouse retinas. Range of colors (red to blue) indicates the range of expression values (high to low).(B) Pathway enrichment analysis of differentially expressed genes in *UBC*Δ*CTGF* versus WT mouse retinas. The clusters with functional terms that reached significance of p \< 0.05 are shown. Online functional databases were used to extract each term.(C--E) Enrichment plot of the gene set of (C) tip cell, (D) angiogenesis, and (E) ECM/cell adhesion pathways. Genes that appear before or at the peak are defined as core enrichment genes for that gene set. Genes whose expression levels are most closely associated with the *CTGF*^+/+^ group are located at the left, whereas genes from the *UBC*Δ*CTGF* gene set within the ranked list are located at the right.See also [Figure S4.](#mmc1){ref-type="supplementary-material"}

CTGF-Dependent Transcriptional Program Targets YAP Network Genes {#sec2.5}
----------------------------------------------------------------

YAP was among the most remarkable transcriptional regulators and key angiogenic factors that were differentially expressed as a result of *CTGF* deletion ([Figures 4](#fig4){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}D). Like *CTGF*, *YAP* expression has been reported to increase in the retinal vasculature at an early stage of development ([@bib16], [@bib48]). YAP is also required for the VEGF-VEGFR2 signaling axis that controls angiogenesis ([@bib71]). VEGF-induced YAP activation leads to cytoskeletal remodeling, which orchestrates cellular decisions of proliferation, differentiation, cell shape, and polarity ([@bib32]). To investigate the role of YAP in the underlying mechanisms of *CTGF*-dependent regulation of angiogenesis, we determined whether the transcriptomic changes associated with *CTGF* deficiency correlated with those caused by YAP deletion (or overexpression). Using GSEA and previously reported data for YAP overexpression in the Msig ([@bib44]), we found that numerous genes that were upregulated upon YAP stimulation were decreased by *CTGF* deletion (e.g., Filamin A, ASAP1, CRIM1, SLIT2) ([Figures 5](#fig5){ref-type="fig"}A--5D). Reversibly, genes that were downregulated upon YAP stimulation were upregulated upon *CTGF* deletion (e.g., Cox8A, RAB40C). For further *CTGF* target gene data validation, we analyzed 11 differentially expressed YAP network genes by qPCR. As shown in [Figure 5](#fig5){ref-type="fig"}E, the expression of 9 of the 11 genes was fully consistent with their RNA-seq expression profiles and trends (p \< 0.05), suggesting that the *CTGF*-dependent transcriptional program is, at least in part, linked to YAP regulatory activities. As *CTGF* is itself a YAP target gene ([@bib76]), the expression and activity of *CTGF* and YAP are mutually regulated.Figure 5CTGF-Dependent Transcriptional Program Targets YAP Network Genes(A and B) Heatmaps of the top 32--43 enriched genes identified by GSEA showing differential regulation of YAP signature genes in retinas of *UBC*Δ*CTGF* mice. Enrichment of CTGF signature with genes up-regulated in MCF10A cells (breast cancer) over-expressing YAP gene and YAP conserved signature/Hippo pathway genes are shown in (A) and (B), respectively.(C and D) Running enrichment score for the gene set analyses shown in (A) and (B) as the analysis walks along the ranked list.(E) Relative mRNA levels of YAP target genes in retinal lysates of *CTGF*^+/+^ and *UBC*Δ*CTGF* mice. The mRNA levels in CTGF^+/+^ mice were set to 1. Each measurement was performed in triplicate. (∗p \< 0.05, n = 3).

YAP-Mediated Rescue of Vascular Defects Caused by *CTGF* Deficiency {#sec2.6}
-------------------------------------------------------------------

To further examine the extent of YAP involvement in *CTGF*-dependent effects on vascular development, we determined whether ectopic re-expression of *YAP* could rescue the vascular defects associated with *CTGF* deletion. To this end, *YAP* was ectopically expressed through adeno-associated virus isotype 6 (AAV6)-mediated gene transfer ([Figure 6](#fig6){ref-type="fig"}A). Retro-orbital injection of a control *AAV6-GFP* vector into P1 mouse pups produced efficient expression of the *GFP* transgene in ECs lining retinal blood vessels at P7 ([Figure 6](#fig6){ref-type="fig"}B). Quantitative analyses of the retinal vascular phenotype at P7 showed that AAV-mediated re-expression of *YAP* significantly increased vascular area and junction density in *UBC*Δ*CTGF* mice compared with those injected with the AAV6-control transgene (i.e., AAV6-Luciferase or AAV6-Luc) ([Figures 6](#fig6){ref-type="fig"}C--6E). Similarly, BrdU^+^ cell count was significantly increased upon re-expression of YAP in *CTGF*-deficient mice, which is consistent with increased cell proliferation in sprouting vessels ([Figure 6](#fig6){ref-type="fig"}F). qPCR-based analyses of mRNA contents showed that YAP re-expression primarily affected genes involved in cell adhesion and migration (e.g., *CCN1*, *TSPAN*, *CRIM1*), proliferation (e.g., *ECT2*, *SLIT2*), differentiation (e.g., *HEY1*), and ECM remodeling (e.g., *TIMP3*) ([Figure 6](#fig6){ref-type="fig"}G). These gene targets are under direct or indirect regulation by YAP ([@bib34], [@bib33]), suggesting that YAP acts as a relay for *CTGF*-dependent control of EC growth.Figure 6YAP-Mediated Rescue of Vascular Defect Caused by *CTGF* Deletion(A) Schematic representation of *AAV6*-mediated rescue protocol of *CTGF* deletion following AAV6-mediated expression of *YAP*. The *AAV6* vector is injected at P1 followed by 4HT injection at P2, P3, and P4 to induce *CTGF* deletion. Vascular phenotype is analyzed at P7.(B) Flat-mount images of IB4-stained retinas from *CTGF*^*+/+*^ mice at P7 following retro-orbital injection of *AAV6-GFP*. Note that *GFP* expression is largely found in the retinal vascular endothelium lining blood vessels.(C) IB4-stained retinal mounts of *CTGF*^+/+^ (a) and *UBC*Δ*CTGF* (b and c) mice following retro-orbital injection of either *AAV6-luc* (a and b) or AAV6-*YAP* (c). Analyses of vascular parameters (i.e., vascular area and junction density) performed with AngioTool software are shown in (d--f) as described in [Figure 2](#fig2){ref-type="fig"}A.(D and E) Graphical representations of the changes in vascular area, junction density, and lacunarity between control and experimental groups described in [Figure 6](#fig6){ref-type="fig"}C. ∗∗p \< 0.001 and ∗p \< 0.05 versus *CTGF*^+/+^ (n = 4).(F) Proliferation index as determined by BrdU^+^ nucleus counts in retinal mounts of *CTGF*^+/+^ and *UBC*Δ*CTGF* mice following retro-orbital injection of either *AAV6-luc* or *AAV6-YAP*. Data are means ± SE. ∗*p \<* 0.05; ∗∗p\<0.001.(G) Relative mRNA levels of YAP target genes in retinal lysates from *CTGF*^+/+^ and *UBC*Δ*CTGF* mouse retinas. The mRNA levels in *CTGF*^+/+^ mouse retinas were set to 1. Each measurement was performed in triplicate. (∗p \< 0.05, *n* = 3).

Regulation of the Paracellular Vascular Barrier through CTGF-YAP Functional Interaction {#sec2.7}
---------------------------------------------------------------------------------------

Next, we determined whether *YAP* re-expression may also improve vascular permeability defects associated with *CTGF* deletion. As shown in [Figure 7](#fig7){ref-type="fig"}A, FITC-albumin extravasation was markedly reduced in *UBC*Δ*CTGF* mouse retinas transduced with AAV6-YAP compared with those transduced with the AAV6-Luc control. When normalized to the vascular area, re-expression of *YAP* significantly reduced vascular leakage in *CTGF* mutant mouse retinas compared with their control counterparts ([Figure 7](#fig7){ref-type="fig"}B).Figure 7Regulation of the Paracellular Vascular Barrier through CTGF-YAP Functional Interaction(A and B) (A) Retinal flat mounts of *CTGF*^+/+^ (a) and *UBC*Δ*CTGF* (b and c) mice following retro-orbital injection of FITC-albumin. *CTGF*^+/+^ and *UBCΔCTGF* mice were transduced with either *AAV6-luc* (a and b) or *AAV6-YAP* (c). AAV vector injection and 4HT-induced *CTGF* exon recombination were as described in [Figure 6](#fig6){ref-type="fig"}A. Vascular permeability index in these groups is shown in (B). ∗p\<0.05.(C) Diagram outlining paracellular and transcellular transports in the endothelium.(D and E) (D) GSEA-generated heatmap of CTGF transcriptome enrichment with transcellular transport proteins. Range of colors (red to blue) indicates the range of expression values (high to low). The enrichment score (ES) plot for transcellular gene set is shown in (E).(F--K) Relative mRNA levels of transcellular (e.g., (F) *PLVAP*) and paracellular (e.g., (G) *CDH5*, (H) *OCLN*, (I) *PECAM1*, (J) *CLDN5,* and (K) *YAP*) in retinal lysates of *CTGF*^+/+^ and *UBCΔCTGF* mice. Each experimental point was performed in triplicate. (∗∗p \< 0.05, *n* = 3).(L) High-magnification images of retinal vessels of P7 *CTGF*^+/+^ and *UBCΔCTGF* mice stained with CDH5 antibodies. Single-channel images of retinal capillaries are shown. Straight mature CDH junctions are shown with red arrows. Vesicular endocytic CDH5 vesicles are shown with black arrows.(M) A representative image of western blot analysis of CDH5 and pCDH5 (Tyr 731) in retinal lysates from WT and *UBC*ΔCTGF mice. GAPDH was used as a loading control.

A defining feature of a functional retinal barrier is (1) a low rate of receptor- and transporter-mediated endocytosis (i.e., transcellular permeability) across ECs and (2) the expression of TJ and AJ proteins that limit paracellular permeability between adjacent ECs ([@bib53]) ([Figure 7](#fig7){ref-type="fig"}C). Proteins involved in transcellular (endocytic) transport include plasmalemma vesicle-associated protein (PLVAP), dynamin-1 and dynamin-2, pacsin 2, flotillin-1 and flotillin-2, Msfd2a, and the glucose transporter Glut1 ([@bib9]). Our GSEA data showed that the transcriptomic changes associated with *CTGF* deletion did not include these transcellular permeability genes ([Figures 7](#fig7){ref-type="fig"}D and 7E). The mRNA levels of *PLVAP*, one of the most important endothelial genes encoding a structural protein of fenestral and stomatal diaphragms ([@bib69]), were not affected by either loss of *CTGF* function or *YAP* re-expression ([Figure 7](#fig7){ref-type="fig"}F), suggesting that CTGF signals do not target genes encoding transcellular transport proteins.

Next, we examined the effects of CTGF signals on EC-EC junction proteins that regulate the paracellular barrier in the retina. Quantitative analyses by qPCR showed that the expression of *cadherin 5* (also known as *CDH5* or *VE-cadherin*), *occludin* (OCLN), and *PECAM1* was not altered in *UBC*Δ*CTGF* compared with *CTGF*^+/+^ retinas ([Figures 7](#fig7){ref-type="fig"}G--7I). In addition, re-expression of *YAP* in *UBC*Δ*CTGF* mice did not influence the transcription of these junctional protein genes either, except for *Claudin 5* (*CLDN5*). *CTGF* deletion significantly reduced *CLDN5* expression, although ectopic *YAP* expression had no effect on *CLDN5* gene transcription in the retina ([Figure 7](#fig7){ref-type="fig"}J). *CLDN5* deficiency in mice was reported to affect vascular barrier to small (\<0.8 kDa) molecules only ([@bib50]). As such, changes in Claudin 5 protein levels alone may not account for the vascular barrier breakdown in *CTGF*-deficient mice.

Meanwhile, even though the expression of *CDH5*, the EC-specific core regulator of vascular integrity and quiescence, was unchanged in *CTGF* mutant versus WT retinas, CDH5 phosphorylation is a major regulatory step leading to increased trans-vascular flux of fluid and proteins. CDH5 cytoplasmic phosphorylation displaces p120-catenin and β-catenin from AJs, thereby increasing endothelial permeability ([@bib19]). Immunohistochemical analysis of the pattern of CDH5 distribution showed that both WT and *CTGF* mutant retinal vessels exhibited straight CDH5-stained junctions characteristic of stable mature junction as well as endocytic CDH5 vesicles typical of CDH5 turnover and remodeling activities ([Figure 7](#fig7){ref-type="fig"}L). However, analysis of phosphorylated CDH5 did not reveal changes in CDH5 phosphorylation at Tyr 731 between WT and *CTGF* mutant retinas ([Figure 7](#fig7){ref-type="fig"}M), suggesting that CTGF regulation of the paracellular barrier may not be controlled through a CDH5 phosphorylation cascade. Importantly, because YAP is also a component of AJ and TJ complexes, it is reasonable to surmise that the remarkable reduction of YAP expression in *CTGF*-deficient mice ([Figure 7](#fig7){ref-type="fig"}K) could be responsible for the associated vascular leakage.

Reduced YAP Levels Destabilized Junctional Complexes in *CTGF*-Deficient ECs {#sec2.8}
----------------------------------------------------------------------------

YAP has been shown to associate with junctional protein complexes in stabilized TJs and AJs ([@bib25], [@bib48]). To examine the role of the *CTGF*/YAP axis in the regulation of the paracellular barrier, we derived ECs from the brain tissue of *UBC*Δ*CTGF* mice and their WT littermates and cultured them to confluence for subsequent *in vitro* experiments. Under normal culture conditions, *CTGF*-deficient ECs showed reduced levels of YAP at the mRNA and protein levels ([Figures 8](#fig8){ref-type="fig"}A--8C). BrdU^+^ cell count was significantly reduced in *CTGF*-deficient ECs, which is consistent with the role of CTGF and YAP in promoting EC proliferation ([Figure 8](#fig8){ref-type="fig"}D). In *CTGF*^+/+^-derived cells, YAP localized to the cytoplasm, nucleus, and cell-cell junctions ([Figure 8](#fig8){ref-type="fig"}E). Co-immunoprecipitation and western blot analyses revealed that YAP forms a complex containing CDH5/VE-cadherin and α-catenin, corroborating the association of YAP with junctional proteins ([Figure 8](#fig8){ref-type="fig"}F). However, the levels of YAP-containing protein complexes were markedly reduced in *CTGF*^−/-^-derived cells. Furthermore, phalloidin-labeled, ZO1-stained cells showed that *CTGF* mutant ECs exhibited numerous intercellular gaps wherein cell borders (delineated by ZO1 staining) change from straight to zigzag lines ([Figure 8](#fig8){ref-type="fig"}G), which is indicative of and consistent with disrupted cell-cell junctions. Adenovirus-mediated re-expression of *YAP*, at least in part, reduced intercellular gaps and re-established continuous cell-cell demarcation lines. Together, these observations suggest that CTGF-induced *YAP* expression is, at least in part, critical for both EC growth and formation and maintenance of stable junctional complexes at cell-cell contacts.Figure 8Reduced YAP Levels Destabilized Junctional Complexes in *CTGF*-Deficient ECs(A) Expression of CTGF and YAP proteins in ECs explanted from *CTGF*^+/+^ and *UBC*Δ*CTGF* (i.e., *CTGF*^−/-^) mouse brain as determined by western blotting. GAPDH was used as a loading control.(B and C) Relative *YAP* (B) mRNA and (C) protein levels in EC lysates of *CTGF*^*+/+*^ and *CTGF*^−/-^ mice. ∗p \< 0.05 (n = 3).(D) Proliferation index of ECs cultured from *CTGF*^+/+^ and *CTGF*^*−/−*^ mice as determined by cell count. ∗p \< 0.05 (n = 3).(E) Immunohistochemical localization of YAP in ECs explanted from *CTGF*^+/+^ mouse brain mice. Colocalization with ZO-1 is shown.(F) Immunoprecipitation of cultured EC protein extracts from *CTGF*^+/+^ and *CTGF*^−/-^ mice. Protein extracts were immunoprecipitated with anti-CDH5 and anti-α-catenin, and further immunodetection was performed with antibodies against YAP.(G) Immunohistochemical staining with phalloidin and ZO-1 antibody of *CTGF*^+/+^ and *CTGF*^−/-^ mouse ECs grown to confluence. Arrows indicate location of intercellular gaps at EC-EC junctions. A representative image of adenovirus-mediated re-expression of *YAP* is shown.

Discussion {#sec3}
==========

The matricellular protein CTGF is known to achieve numerous cell type-specific functions in the immediate microenvironment of the cells. CTGF signals regulate cell proliferation, differentiation, adhesion, migration, and epithelial-mesenchymal transition ([@bib37], [@bib40]). These effects are mediated by a CTGF interactome that includes integrin and non-integrin receptors, other cell surface molecules (e.g., HSPGs, LRPs), ECM, and growth factors ([@bib38]). CTGF-integrin interactions induced angiogenesis in rat cornea ([@bib5]) and in chick chorioallantoic membranes ([@bib61]). However, CTGF was also shown to inhibit angiogenesis *in vitro* by physically interacting with and sequestering VEGF in an inactive form ([@bib30]). Although these *in vitro* and *ex vivo* studies provided insightful information about the molecular properties of the CTGF protein, they did not integrate exogenous cues such as exposure to heterogeneous cell-cell interactions, flow and associated shear stress effects, and tissue-derived signals.

Using transgenic mouse models, targeted gene disruption, and "omic" approaches, we showed that CTGF provides a unique microenvironment in the vascular wall that fine-tunes angiogenesis and ensures barrier integrity. First, we showed that *CTGF* was robustly expressed primarily in endothelial stalk cells and secondarily in pericytes and glia during postnatal retinal vascular development and its expression persisted in the adult vasculature. In ECs, the expression was limited to cells making new cell-cell contacts, whereas ECs prone to occupy the tip cell position were CTGF-negative. These observations are in congruence with previous reports describing widespread expression of *CTGF* mRNA in the embryonic vascular system and constitutive regulation of the *CTGF* gene in ECs ([@bib22], [@bib31]). Hemodynamic forces, which play a critical role in determining the synthetic phenotype and function of ECs, are major inducers of *CTGF* gene expression ([@bib13], [@bib74]). Indeed, tip cells at the sprouting vascular front experience very low levels of shear ([@bib6]) and minimally express, if at all, CTGF, suggesting that blood flow-induced shear deformation, which increases EC capacity to orient in the direction of the flow in newly lumenized vessels, is a potentially important inducer of *CTGF* gene expression in the endothelium. Interestingly, a study by Friedrichsen et al. revealed a dichotomized *CTGF* expression pattern in mouse embryos with higher *CTGF* mRNA levels in the pressured arteries (e.g., aorta, pulmonary, and peripheral arteries) than low-pressured veins (e.g., vena cava) ([@bib22]). Congruently, our findings in the CTGF promoter reporter mouse retina showed that the *CTGF*:*GFP* reporter was expressed in ECs of the arterial and capillary walls, whereas venous ECs minimally expressed the CTGF:GFP reporter. Thus, the underlying basis for differential expression of *CTGF* between arterial and venous ECs is conceptually valid and strong. However, differential *CTGF* mRNA levels between ECs cultured from arterial (e.g., coronary arteries) and venous (e.g., HUVECS) vessels could not be detected when these cells were cultured under static conditions (data not shown), suggesting that differential pressure signals between arteries and veins could account for variations of CTGF gene regulation in arterial and venous ECs. However, it is noteworthy that the *CTGF*:*GFP* reporter was expressed in mural ensheathing cells of arteries, capillaries, and veins. This observation is at variance with Friedrichsen et al.\'s study, which did not show *CTGF* mRNA signals in venous mural cells such as those of the vena cava. Such discrepancy between those findings and ours may be attributed to the methodology used to detect *CTGF* mRNA and protein signals, or it could be attributed to differences between the vascular bed types analyzed, blood vessel diameter/caliber, and/or three-dimensional geometry of the vessels. In addition, the confounding effects of transcriptional and post-transcriptional regulatory mechanisms of the *CTGF* gene could also account for differences in mRNA and protein signals.

Our data further demonstrated that global or EC-specific deletion of *CTGF* altered normal retinal vascular development. Loss of CTGF function at postnatal stages caused hypovascularization of the retina and altered vascular permeability, recapitulating the vascular defects characteristic of early-onset familial exudative vitreoretinopathy in humans ([@bib36]). *CTGF* deficiency reduced vascular area, density, and junctional point numbers, and increased vascular lacunarity, which was correlated with a significant decrease of EC proliferation. However, *CTGF* deficiency did not alter tip cell number and hierarchical specification of the vasculature into arteries, capillaries, and veins, indicating that *CTGF* expression does not affect the dynamics of EC phenotypical plasticity. Interestingly, global or EC-specific deletion of *CTGF* produced vascular defects similar to those associated with deletion of transcription factors such as *SRF* and *MRTF-A* ([@bib72]), two versatile transcription factors that toggle between disparate programs of gene expression related to cell growth and differentiation ([@bib63]). Indeed, the *CTGF* gene is one of the CArG-box-containing promoter genes (i.e., CarGome) that is activated by the SRF/MRTF duo. Thus, CTGF can potentially act as an SRF/MRTF downstream effector molecule, mediating their regulatory effects on EC growth and function.

A previous study by Hall-Glenn et al. showed that a global *CTGF* deficiency in mice induced minor enlargement of blood vessels and local edema in the *CTGF* mutant dermis ([@bib27]). These changes have been attributed to incomplete coverage of microvessels by pericytes in the dermis of *CTGF* mutant mice. However, it was unclear whether the observed vascular phenotype was due to direct effects in ECs or secondary CTGF effects in other cell types. Our data showed that the angiogenic defects associated with CTGF deletion were largely due to the loss of EC-derived CTGF as EC-specific deletion of *CTGF* recapitulated, at least in part, those of its ubiquitous deletion. Because loss of *CTGF* function reduced EC proliferation, and sprouting, it appears to potentiate the effects of other regulators of angiogenesis. It is noteworthy that the loss of pericyte-derived CTGF minimally, if at all, altered vascular growth and integrity. The importance of pericytes in the development and function of microvessels has been well established, as illustrated by the phenotype of mice in which pericyte development has been disrupted ([@bib21]). Therefore, targeting an important component of their secretome would be expected to have a greater impact during angiogenesis. More than one explanation is possible to rationalize the lack of retinal vascular defects in mice with pericyte-specific *CTGF* deletion. First, pericyte-specific knockdown of CTGF was not fully penetrant due to the expression of CTGF by cells other than NG2^+^ cells. Under these circumstances, the role of CTGF produced by ECs and glia may be magnified, fully compensating for the absence of pericyte-derived CTGF. Second, pericyte-specific deletion of *CTGF* was produced using transgenic mice expressing the Cre recombinase under the control of the *NG2* (aka *Cspg*4) promoter/enhancer. As *NG2* expression is restricted to arteriolar and capillary perivascular cells during angiogenesis ([@bib11]), Cre-mediated *CTGF* gene targeting with the *NG2* promoter may be limited to NG2^+^ cell subpopulation of pericytes only, and this was inconsequential on the vascular phenotype. Third, the retinal model of angiogenesis that was used in our experiments is based on postnatal angiogenesis, even though the bulk of developmental angiogenesis occurs during embryonic stages. Therefore, it was not surprising that constitutive deletion of *CTGF* was reported to cause incomplete coverage of microvessels by pericytes in the dermis of *CTGF* mutant embryos ([@bib27]). This suggests that *CTGF* deficiency in pericytes may have a lesser impact during the postnatal than embryonic stages. Last, the effects of pericyte-derived CTGF may be minimal during normal postnatal angiogenic events but more effective in pathological events. Future studies addressing this hypothesis are warranted.

Molecularly, several clusters of genes and pathways involved in the regulation of important processes such as EC proliferation, migration, and junction formation were affected by *CTGF* deficiency. The expression of *IGF-1*, *TGF-β1*, *TGF-β2*, *FGF-10*, and *angiopoietin 1* was downregulated upon *CTGF* deletion, and reduced expression of these growth factor genes may account for the subsequent hypovascularization of the retina. Similarly, loss of *CTGF* function decreased the expression of several key basement membrane (BM) protein genes such as *laminin 4*, *collagen 4A1*, *SPARC*, and *tenascin C* as well as other FACIT collagens and proteoglycans, many of which are important for the stability and compliance properties of the vascular wall.

In addition, several transcription factors and co-cofactors showed differential gene expression patterns between WT and mutant *CTGF* mouse retinas including *YAP*, *NFAT5*, and *SRF*. *CTGF* deletion significantly decreased the expression of these transcriptional regulators, many of which affect important aspects of vascular cell growth and differentiation. *YAP* regulation by CTGF signals is of particular significance as, thus far, *YAP* has been shown to be regulated largely at the post-translational levels by G-protein-coupled receptors (GPCR), mechanical forces, growth factors such as VEGF, actin dynamics, and Lats1 activity ([@bib2], [@bib4]). The regulation of *YAP* expression by CTGF is highly significant in developmental angiogenesis, although the transcriptional or post-transcriptional mechanisms underlying such regulation remain to be determined. The autonomous role of YAP on vessel development has previously been reported in several independent studies using EC-specific deletion of *YAP* and *TAZ*, a paralog of *YAP* that also regulates gene expression through binding to YAP-interacting partners ([@bib29]). Double knockout of *YAP* and *TAZ* in the endothelium decreased vascular density, branching, and sprouting ([@bib16]), mimicking, at least in part, the *CTGF* loss-of-function phenotype. Concordantly, we found a significant gene profile overlap of CTGF and YAP target genes. It is conceivable that *YAP* expression and activity in ECs build a transcriptional response that sustains CTGF signals by coordinating the expression of sets of genes and proteins that regulate various aspects of sprouting angiogenesis.

YAP is a critical control node in cell fate decisions of proliferation, differentiation, survival, or apoptosis. Nuclear YAP physically interacts with DNA-binding transcription factors such as RUNX family, thyroid TF1 (TTF-1), TBX5, PAX3, PAX8, peroxisome proliferator-activated receptor γ, and TEAD to stimulate or repress the expression of downstream target genes ([@bib52]). The TEAD family of transcription factors plays an important role in YAP-dependent gene regulation and cell growth stimulation. The TEAD consensus sequences were found in at least 75% YAP target genes, as YAP and TEAD1 co-occupied \>80% of the promoters pulled down by chromatin immunoprecipitation ([@bib75]). Surprisingly, our data showed that whereas *YAP* gene expression was downregulated upon *CTGF* deletion, the expression of *TEAD1* was upregulated in the *CTGF*-deficient mouse retina. These findings raise the question whether YAP and TEAD act independently of one another to control separate angiogenic programs. Recent studies provided an answer to this question. By investigating the biology of GPCR-activated YAP/TAZ during retinal angiogenesis, Yasuda et al. have shown that YAP acts independently of TEAD to suppress the expression of Dll4, a transmembrane ligand for the Notch family of receptors, which prevents overexuberant angiogenic sprouting ([@bib73]). This suggests an essential role of TEAD-independent YAP activities in retinal angiogenesis. This is also consistent with other findings by Zhao et al. showing that TEAD binding-defective YAP-S94A mutant can still induce expression of a fraction of the YAP-regulated genes ([@bib76]). Further studies will be needed to tease apart the full spectrum of YAP-independent TEAD and TEAD-independent YAP functions in angiogenesis and determine whether increased TEAD1 expression in CTGF-deficient mice preserves/bolsters YAP-independent TEAD1 angiomodulatory activities. Importantly, CTGF and YAP are both molecular effectors and downstream targets of mechanical forces, as their expression and activity have been associated with cells exposed to mechanical stresses, such as shear stress, stretching, or stiffness of the surrounding ECM ([@bib7], [@bib20], [@bib70]). A study by Nakajima et al. in zebrafish demonstrated that endothelial YAP functions in response to flow to maintain EC function in blood vessels ([@bib46]). The flow-induced reorganization of F-actin was associated with the release of YAP from angiomotin and its nuclear translocation during vessel growth. Molecularly, CTGF signals and YAP activity seem to reinforce the cell cytoskeleton and contractile apparatus, and through these mechanisms, they respond to and control the actomyosin-generated internal forces in the cells ([@bib48]). Thus, both hemodynamic and internally generated forces in ECs potentially fuel and sustain a CTGF/YAP feedforward loop that sustains angiogenesis during vascular development.

Another important outcome of our study design is that CTGF is an important determinant of blood vessel integrity and stability. Barriergenesis in the developing retina involves the coordinated induction of proteins that maintain TJs and AJs and nutrient transporters across ECs ([@bib51]). Thereafter, maturation of the barrier properties is achieved as functional and physical interactions occur with pericytes, astrocytes, and Müller cells. Assembly and maturation of junctional complexes between ECs are dependent on actomyosin dynamics regulated by the activity of small Rho GTPases such as RhoA and Cdc42 ([@bib1]), which appears to be required for maintenance of blood barrier integrity during adulthood as well. However, the acquisition of endothelial barrier properties in *CTGF*-deficient retinas was not due to defects in transcellular transport because mutant *CTGF* mice showed no differences in the expression of *PLVAP* and other membrane proteins that localize to fenestrae and caveolar stomatal diaphragms of ECs. Instead, paracellular barrier protein association and organization seemed to have been altered in *CTGF*-deficient blood vessels. *CTGF* deletion similarly altered the barrier properties of preformed vessels in adult mice suggesting that basal expression of CTGF is critical for not only barrier formation but also its maintenance. It is noteworthy that vascular leakage was not associated with active hemorrhage sites in the retina and brain in *CTGF*-deficient mice. Similarly, the initial characterization of mice with constitutive deletion of CTGF did not report visible signs of hemorrhage during embryonic and fetal development ([@bib31]), even though defects in ECM formation or loss of genes crucial for EC-EC and EC-ECM interaction generally led to severe hemorrhagic phenotypes ([@bib67]). However, CTGF is different from common ECM proteins because, as a matricellular protein, CTGF does not subserve a structural role in the cell environment, but functions as an extracellular cue that optimizes the function of growth factors and ECM proteins. The absence of severe hemorrhage in *CTGF* mutant mice also raises the possibility of potential functional compensation for *CTGF* deficiency by CCN1, a closely related homolog of CTGF. Both genes are highly expressed in the vascular system and have similar activities *in vitro* ([@bib12], [@bib42]). Although CTGF and CCN1 orchestrate complementary aspects of developmental angiogenesis, they may also serve redundant functions in vascular elements ([@bib14]). Studies designed to contrast the vascular phenotypes of *CTGF*, *CCN1*, and *CTGF/CCN1* double mutants will be informative in this regard.

Last, our data showed that CTGF effects on the vascular permeability were, at least in part, dependent on *YAP* expression. Based on *CTGF* loss- and subsequent *YAP* gain-of-function phenotypes, reduced YAP levels in ECs disrupted intercellular junctional complex formation and stabilization. Our coimmunoprecipitation experiments showed that the presence of YAP in protein complexes of CDH5 and α-catenin is in agreement with previous findings that YAP associates with the VE-cadherin complex via 14-3-3 proteins, a family of phosphoserine-binding proteins that prevent YAP shuttling between the cytoplasm and nucleus ([@bib25]). Hyperphosphorylated YAP localizes to adherent junctions in a trimeric complex with 14-3-3 and α-catenin indicating that YAP functions in the cytoplasm, in the nucleus, and at cell-cell junctions. We suggest that the "decision" of the endothelium to become permeable instead of forming a blood-retinal barrier is primarily dependent on YAP levels in different cell compartments. It is anticipated that conditions that perturb the functional interactions between CTGF and YAP likewise alter YAP cellular localization and vascular permeability.

Taken together, our data showed a crucial role for CTGF in regulating the expression and function of a wide array of extracellular and intracellular factors that are essential for normal vascularization of the retina and the acquisition of a functional vascular barrier. It is conceivable that genes affected by CTGF in the endothelium might be relevant for angiogenesis and barriergenesis in organs other than the retina as well. It also is highly likely that the deregulation of the CTGF network genes is relevant in pathological angiogenesis processes (e.g., diabetic retinopathy, retinopathy of prematurity) characterized by disrupted growth, lack of vessel maturation, defective remodeling, and/or barrier dysfunction. Future studies focused on the regulation and function of the CTGF/YAP angiomodulatory pathway in *in vivo* models of vascular diseases are warranted.

Limitations of the Study {#sec3.1}
------------------------

The transcriptomic differences between WT and mutant CTGF mouse retinas together with previously reported vascular defects associated with loss of function of CTGF targets provided greater insights into the essential role of CTGF in retinal angiogenesis and barriergenesis. Equally important, however, is information about the retinal microvascular ultrastructure in CTGF mutant mouse retina, which is a limitation of this study. Transmission electron or two-photon microscopy is the method of choice to be used in future studies to observe and further examine retinal vessel micromorphology and assess potential loss of EC contiguity, as well as the ultrastructural changes of endothelial TJs. Nevertheless, there are prior ultrastructural analyses showing that dermal capillaries of *CTGF*-deficient mouse embryos had multiple protrusions as well as ultrastructural defects in microvascular endothelial BM protein assembly ([@bib27]). These observations are consistent with our data showing that *CTGF* deletion reduced the expression of numerous BM proteins (e.g., *laminin 4*, *elastin*, *fibrillin-2*, *glypican 5*, *collagen 4A1*, *and tenascin-C*). In particular, defective expression and deposition of type IV collagen and laminin 4 in *CTGF*-deficient mice could at least in part, engender ultrastructural disorganization/discontinuity of the capillary BM and breakdown of the vascular barrier as seen in acute and chronic neuropathological settings ([@bib39]). As previously shown by Poschl et al., deletion of *type IV collagen α*~*1*~ or *α*~*2*~ *subunit* gene did not prevent BM formation and assembly, but reduced its stability ([@bib56]), indicating that type IV collagen is critical for the integrity of the microvasculature wall. Similarly, mice lacking *laminin 4*, exhibited a discontinuous capillary BM and vascular leakage during the embryonic and neonatal period ([@bib66]). Clearly, by targeting the BM protein and growth factor genes, CTGF affects the maturation and barrier function of the developing blood vessels and potentially their force-bearing capabilities during neonatal life.
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